Education
- 1981: Degree in Oncology
- 1979: Degree in Pharmacology
- 1978: Graduated in Medicine and Surgery, University of Milan
- 1978: Post-graduated internship, Gynecological Oncology Department, University of Milan
- 1977: Graduate summa cum laude
- 1971: Graduated from High School (Liceo Scientifico)
Academic Appointments
- Head, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS
- Professor and Internal examiner of the International Graduate Program of the Istituto di Ricerche Farmacologiche Mario Negri organized in collaboration with the Open University, which confers the PhD title
- Professor of the Advanced School in Pharmacological Sciences of the Istituto di Ricerche Farmacologiche Mario Negri, which confers the title of āDottore di Ricercaā
Awards and Honors
- 2018: Recipient of the Guido Venosta FIRC Award for Cancer Research by the President of the Republic of Italy
- 2015: Recipient of the āProdiā Award in recognition of his scientific carrier
- 1986: Recipient European School of Oncology Award for Cancer Chemotherapy
- 1981: Rank number one in specialization in Oncology
His studies have been essential to guide the preclinical and clinical investigation of the marine natural product trabectedin, a drug currently used worldwide for the therapy of soft tissue sarcomas and some other solid malignancies. Recently he has identified novel mechanistically-driven combinations of trabectedin with other drugs. These combinations have been successfully tested in preclinical models of liposarcomas and are currently under investigation in the clinic. Over the years he has elucidated the mode of action and the pharmacological properties of several novel compounds, some of which have been developed in the clinic as anticancer agents. His team has developed methods to determine drugs in tumors by applying a variety of methods including Imaging Mass Spectrometry demonstrating that resistance against treatment is not only related to molecular changes of drug targets, but also to low and heterogeneous tumor penetration of anticancer agents. His recent preclinical and translational research has been mainly focused on soft tissue sarcomas, mesotheliomas and ovarian cancer. As far as ovarian cancer his team has recently identified molecular biomarkers that can be used to optimize and monitor the therapy and are potentially exploitable for an early diagnosis of this disease.
- Paracchini L., Beltrame L., Grassi T., Inglesi A., Fruscio R., Landoni F., Ippolito D., Delle Marchette M., Paderno M.C., Adorni M., Jaconi M., Romualdi C., DāIncalci M., Siravegna G., Marchini S. . Clin. Cancer Res., 27(9): 2549-2559 (2021)
- Frapolli R., Bello E., Ponzo M., Craparotta I., Mannarino L., Ballabio S., Marchini S., Carrassa L., Ubezio P., Porcu L., Brich S., Sanfilippo R., Casali P.G., Gronchi A., Pilotti S., D’Incalci M. . Clin. Cancer Res., 25: 7565-7575 (2019).
- Garattini S., Fuso Nerini I. ,DāIncalci M. . Oncol., 29: 13-19 (2018).
- Di Giandomenico S., Frapolli R., Bello E., Uboldi S., Licandro S.A., Brich S., Mauro V., Tamborini E., Pilotti S., Casali P., Grosso F., Sanfilippo R., Gronchi A., Mantovani R., Galmarini C., Fernandez Sousa-Faro J.M., DāIncalci M. . Oncogene, 33(44): 5201-5210 (2014).
- Germano G., Frapolli R., Belgiovine C., Anselmo A., Pesce S., Liguori M., Erba E., Uboldi S., Zucchetti M., Pasqualini F., Nebuloni M., Van Rooijen N., Mortarini R., Beltrame L., Marchini S., Fuso Nerini I., Sanfilippo R., Casali P.G., Pilotti S., Anichini A., Mantovani A., DāIncalci M., Allavena P. . Cancer Cell, 23(2): 249-262 (2013).